Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

Also called NCT01084005

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01084005
  • EudraCT 2009-015255-25
Other papers using this trial's data
  • Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial Lancet (London, England), 2013-10-26 DOI, PubMed 23948125

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
Australia, Canada, Denmark, Netherlands, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01084005. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-07-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
linagliptin
Intervention (Drug)
placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01084005
Content hash
b38f78012ee4dddfbab122ecf43c7575811a1404fce7bc8dcad3dded0914e206